They’re going for it: David Liu’s preclinical biotech shoots for a (maybe $200M) IPO

John Carroll

Editor & Founder

Can a preclinical biotech with grand ambitions, a star scientific founder and enthusiastic backers with deep pockets fly a big IPO against the gale force …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

They’re going for it: David Liu’s preclinical biotech shoots for a (maybe $200M) IPO

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

How AI can address ongoing challenges in the life sciences industry

They’re go­ing for it: David Liu’s pre­clin­i­cal biotech shoots for a (maybe $200M) IPO

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

They’re going for it: David Liu’s preclinical biotech shoots for a (maybe $200M) IPO